The appointment of a new CFO is an important event for a company, but it does not necessarily have a direct short-term impact on the stock price. Mike Shankman's appointment may bring new perspectives and strategies to Lexaria Bioscience, but the immediate effect on the stock price is uncertain. Therefore, the score is neutral (0), with high relevance (100) and moderate importance (60) for investors.